A 1 minute read
Feb 12, 2020 4:39:38 PM
The Stroke Center at Ascension Sacred Heart Pensacola in Florida is one of only a dozen U.S. hospitals participating in a worldwide clinical research study to evaluate the effectiveness of a new drug that can treat certain patients who experience life-threatening bleeding in the brain.

The clinical trial will measure the effectiveness of the drug andexanet alfa, which can reverse the blood-thinning effects of two medications – apixaban and rivaroxaban – which are frequently prescribed to patients with atrial fibrillation for stroke prevention.

The blood-thinning medications carry a risk for bleeding, and andexanet alfa can reverse their anticoagulant effects in patients with uncontrolled bleeding in the brain.

Sidney Mallenbaum, MD, a neurologist at Ascension Sacred Heart with expertise in stroke care and electrodiagnostic medicine, is serving as the Stroke Center’s principal investigator. He said the randomized clinical trial will compare the new drug with the current standard treatment for acute brain hemorrhage in patients taking these specific blood thinners.

The Stroke Center at Ascension Sacred Heart is the area’s only Comprehensive Stroke Center designated by the Florida Agency for Healthcare Administration. Its neurologists and neurosurgeons have advanced training in rapidly diagnosing and treating strokes. Treatments provided by the Stroke Center team include sophisticated imaging technologies and minimally-invasive procedures to remove blood clots in the brain that cause strokes.

 


Not a Definitive Healthcare newsletter subscriber?


Sign up to receive our latest news and blogs right in your inbox

Sign up for our newsletter

Continue Reading